Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 9/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MELK | Q14680 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3236116 | 0.87 | DDB1 (0.40) | CRBNIKZF3DDB1GRM5DRD2 | |
| SCHEMBL3237578 | 0.86 | DRD2 (0.45) | DRD2DRD4ALDH1A1LMNAHTT | |
| SCHEMBL3243794 | 0.84 | ENPP2 (0.40) | DRD2DRD4ALDH1A1LMNAHTT | |
| SCHEMBL8017379 | 0.83 | MELK (0.43) | CRBNDDB1MEN1KMT2AMELK | |
| SCHEMBL3244109 | 0.82 | PTPN1 (0.40) | ALDH1A1LMNA | |
| SCHEMBL3235754 | 0.82 | MEN1 (0.50) | ALDH1A1HTTMEN1KMT2AMELK | |
| SCHEMBL3232802 | 0.82 | DRD2 (0.43) | DRD2DRD4ALDH1A1 | |
| SCHEMBL8391600 | 0.82 | JAK1 (0.41) | MEN1KMT2AMELK | |
| SCHEMBL3247189 | 0.81 | HRH3 (0.42) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL3243054 | 0.80 | SMN1; SMN2 (0.45) | ALDH1A1HTTMEN1KMT2AMELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009131958-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING TRIAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | claimed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | CFTR, PKD1, PKD2 | CRBN 1259/4885IKZF3 1085/4885DDB1 1506/4885 |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | CRBN 1844/4885IKZF3 2302/4885DDB1 1022/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | CRBN 1844/4885IKZF3 2302/4885DDB1 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.